COMPANY PROFILE / #3604
Broken String Biosciences
Cambridge, United KingdomVenture Capital-Backed
OVERVIEW
Developer of a sequencing platform intended to drive the development of cell and gene therapies that are safer by design. The company's platform combines novel sequencing techniques, bioinformatics analysis, and artificial intelligence, providing healthcare professionals with a data-driven approach to safely introduce the next generation of innovative medicines, including cells and gene therapies.
已融资16.01
最新估值27.86
员工数27
成立年份2020
公司概况
- Companies
- Broken String Biosciences
- Description
- Developer of a sequencing platform intended to drive the development of cell and gene therapies that are safer by design. The company's platform combines novel sequencing techniques, bioinformatics analysis, and artificial intelligence, providing healthcare professionals with a data-driven approach to safely introduce the next generation of innovative medicines, including cells and gene therapies.
- Website
- www.brokenstringbio.com
- HQ Location
- Cambridge, United Kingdom
- Year Founded
- 2020
- Keywords
- genome editing, genome engineering, genome mapping, genome sequencing technology, genomics company, genomics platform
- Competitors
- Paragon Genomics, CD Genomics
- Ownership Status
- Privately Held (backing)
- Company Financing Status
- Venture Capital-Backed
融资与估值
- Total Raised
- 16.01
- First Financing Date
- 01-Jan-2020
- First Financing Size
- —
- First Financing Valuation
- —
- Last Financing Date
- 18-Sep-2023
- Last Financing Deal Type
- Early Stage VC
- Last Financing Size
- 10.23
- Last Financing Valuation
- 27.86
- Last Financing Status
- Completed
- Last Known Valuation
- 27.86
- Last Known Valuation Date
- 18-Sep-2023
- Last Known Valuation Deal Type
- Early Stage VC
- Valuation Estimate
- 40.06
- Valuation Estimate Growth Rate
- 43.79%
- Active Investors
- Cardiff University, CP-Carrillo, Dieter von Holtzbrinck Ventures, First In Ventures, HERAN Partners, Illumina Ventures, Image Frame Investment, Korys Investments, Merieux Equity Partners (Lyon), Tencent Holdings, Time Partners
- # Active Investors
- 11
- Acquirers
- —
团队与联系人
- Employees
- 27
- Employee Growth %
- -32.50%
- Employee History
- 2025: 27, 2024: 40, 2023: 13, 2022: 9, 2021: 3
- Primary Contact
- Felix Dobbs
- Primary Contact Title
- Founder & Chief Operating Officer
- Primary Contact Email
- felixdobbs@brokenstringbio.com
- Primary Contact Phone
- +44 (0)12 2378 6071
增长与经营
- Revenue
- —
- Revenue Growth %
- —
- Growth Rate
- —
- Growth Rate % Change
- —
- Growth Rate Percentile
- —
- Size Multiple
- —
- Size Multiple % Change
- —
- Size Multiple Change
- —
- Size Multiple Percentile
- —
- Majestic Referring Domains
- —
- SimilarWeb Unique Visitors
- —
- SimilarWeb Unique Visitors Change
- —
- SimilarWeb Growth Rate
- —
- SimilarWeb Growth Rate Percentile
- —
- Success Probability Over Time – 1 Year
- 6%
- Success Probability Over Time – 3 Year
- 12%
- Success Probability Over Time – 5 Year
- 23%
记录来源：public.companies · 原始序号 #3604 · 所有字段均按数据库原值展示。